RWJ-49815

RWJ-49815 (24 h) inhibits the growth of Saccharomyces cerevisiae JF1331 (MIC >20 μg/mL) and Candida albicans CAF2-1 (MIC 5-10 μg/mL) in vitro^[1].
RWJ-49815 (0-100 μM; 60 min) inhibits the autokinase activity of purified Saccharomyces cerevisiae GST-Sln1 in vitro, with an IC₅₀ of approximately 10 μM^[1].
RWJ-49815 (0-10 μM; 5.5 h) inhibits the growth of Saccharomyces cerevisiae strains JF1331 (wild-type SLN1) and JF1735 (sln1Δ ssk1Δ) to an equivalent extent, indicating that its antifungal activity is independent of the inhibition of Sln1 histidine kinase^[1].
RWJ-49815 (0-16 μM) potently inhibits autophosphorylation of Bacillus subtilis KinA protein, with an IC₅₀ of 1.6 μM^[2].
RWJ-49815 (1-128 μg/mL) inhibits the growth of various Gram-positive strains, including drug-resistant MRSA, vancomycin (HY-B0671)-resistant Enterococcus faecium, and penicillin-resistant Streptococcus pneumoniae, with MIC values of 1-2 μg/mL; however, Gram-negative bacteria are resistant to it unless membrane-permeabilizing compounds are used simultaneously^[2].
RWJ-49815 (1-128 μM; 2.25-2.5 h) inhibits the Taz-1 two-component system in Escherichia coli OC3047 in a concentration-dependent manner, and its inhibitory effect on OmpR-dependent reporter gene induction precedes growth inhibition^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.